Author:
Liljedahl Emma,Konradsson Elise,Gustafsson Emma,Jonsson Karolina Förnvik,Olofsson Jill K.,Ceberg Crister,Redebrandt Henrietta Nittby
Abstract
AbstractRadiotherapy can induce an immunological response. One limiting factor is side effects on normal tissue. Using FLASH radiotherapy, side effects could possibly be reduced. The efficacy of FLASH in relation to conventional radiotherapy (CONV-RT) has not been extensively explored in fully immunocompetent animals. Fully immunocompetent Fischer 344 rats were inoculated with NS1 glioblastoma cells subcutaneously or intracranially. Radiotherapy was delivered with FLASH or CONV-RT at 8 Gy × 2 (subcutaneous tumors) and 12.5 Gy × 2 (intracranial tumors). Cured animals were re-challenged in order to explore long-term anti-tumor immunity. Serum analytes and gene expression were explored. The majority of animals with subcutaneous tumors were cured when treated with FLASH or CONV-RT at 8 Gy × 2. Cured animals could reject tumor re-challenge. TIMP-1 in serum was reduced in animals treated with FLASH 8 Gy × 2 compared to control animals. Animals with intracranial tumors survived longer when treated with FLASH or CONV-RT at 12.5 Gy × 2, but cure was not reached. CONV-RT and FLASH were equally effective in fully immunocompetent animals with glioblastoma. Radiotherapy was highly efficient in the subcutaneous setting, leading to cure and long-term immunity in the majority of the animals.
Funder
Fru Berta Kamprads Stiftelse
Cancerfonden
Region Skåne ALF Fund
Lund University
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Wen, P. Y. et al. Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 22(8), 1073–1113 (2020).
2. Skaga, E. et al. Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: To whom do the results of the trials apply?. Neurooncol. Adv. 3(1), vdab008 (2021).
3. Wilson, J. D. et al. Ultra-high dose rate (FLASH) radiotherapy: Silver bullet or fool’s gold?. Front. Oncol. 9, 1563 (2019).
4. Hughes, J. R. & Parsons, J. L. FLASH radiotherapy: Current knowledge and future insights using proton-beam therapy. Int. J. Mol. Sci. 21(18), 6492 (2020).
5. Montay-Gruel, P. et al. Hypofractionated FLASH-RT as an effective treatment against glioblastoma that reduces neurocognitive side effects in mice. Clin. Cancer Res. 27(3), 775–784 (2021).
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献